OI
CRL icon

Oakbrook Investments’s Charles River Laboratories CRL Stock Holding History

Oakbrook Investments’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-4,830
Closed -$738K – 180
2019
Q4 		$738K Sell
4,830
-1,225
-20% -$170K 0.15% 206
2019
Q3 		$802K Buy
6,055
+1,300
+27% +$174K 0.05% 284
2019
Q2 		$675K Sell
4,755
-975
-17% -$132K 0.04% 336
2019
Q1 		$832K Buy
5,730
+50
+0.9% +$6.57K 0.05% 285
2018
Q4 		$643K Sell
5,680
-812
-13% -$102K 0.04% 313
2018
Q3 		$873K Buy
6,492
+1,550
+31% +$191K 0.05% 323
2018
Q2 		$555K Sell
4,942
-555
-10% -$60K 0.04% 331
2018
Q1 		$587K Buy
5,497
+320
+6% +$34.5K 0.04% 321
2017
Q4 		$567K Buy
5,177
+660
+15% +$71.8K 0.04% 331
2017
Q3 		$488K Buy
4,517
+400
+10% +$41.1K 0.03% 347
2017
Q2 		$416K Buy
+4,117
New +$379K 0.03% 362
2017
Q1 		– Sell
-5,042
Closed -$384K – 537
2016
Q4 		$384K Buy
5,042
+150
+3% +$11.4K 0.03% 408
2016
Q3 		$408K Hold
4,892
– – 0.02% 392
2016
Q2 		$403K Buy
4,892
+1,050
+27% +$86.5K 0.02% 405
2016
Q1 		$292K Sell
3,842
-500
-12% -$37K 0.02% 438
2015
Q4 		$349K Buy
4,342
+100
+2% +$7.21K 0.02% 411
2015
Q3 		$269K Hold
4,242
– – 0.02% 463
2015
Q2 		$298K Buy
4,242
+150
+4% +$11.1K 0.02% 449
2015
Q1 		$324K Buy
4,092
+200
+5% +$14.8K 0.02% 454
2014
Q4 		$248K Hold
3,892
– – 0.01% 499
2014
Q3 		$233K Sell
3,892
-400
-9% -$22.9K 0.01% 477
2014
Q2 		$230K Sell
4,292
-100
-2% -$5.49K 0.01% 545
2014
Q1 		$265K Sell
4,392
-100
-2% -$5.83K 0.01% 513
2013
Q4 		$238K Sell
4,492
-300
-6% -$15.1K 0.01% 540
2013
Q3 		$222K Sell
4,792
-700
-13% -$32.1K 0.01% 550
2013
Q2 		$225K Buy
+5,492
New +$235K 0.01% 603

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Oakbrook Investments's CRL Position: Q1 2020 in Review

Oakbrook Investments sold out of Charles River Laboratories (CRL) in Q1 2020, closing a stake of 4,830 shares — an estimated $738K sold.

Oakbrook Investments first reported a position in CRL in Q2 2013 and held it in 26 quarters. The position peaked at $873K in Q3 2018. 414 funds tracked by Wall St. Rank hold CRL as of Q1 2020.

  • Oakbrook Investments reported no remaining Charles River Laboratories position as of Q1 2020 after selling out during the quarter.
  • Oakbrook Investments sold 4,830 Charles River Laboratories shares in Q1 2020, an estimated $738K.
  • Oakbrook Investments first reported a position in Charles River Laboratories in Q2 2013 and held it in 26 quarters.
  • Oakbrook Investments's Charles River Laboratories position peaked at $873K in Q3 2018.
  • 414 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2020.

Based on Oakbrook Investments's 13F filing for Q1 2020, filed 22 Apr 2020.